ZA966577B - Pharmaceutical composition. - Google Patents

Pharmaceutical composition.

Info

Publication number
ZA966577B
ZA966577B ZA9606577A ZA966577A ZA966577B ZA 966577 B ZA966577 B ZA 966577B ZA 9606577 A ZA9606577 A ZA 9606577A ZA 966577 A ZA966577 A ZA 966577A ZA 966577 B ZA966577 B ZA 966577B
Authority
ZA
South Africa
Prior art keywords
pct
date
pharmaceutical composition
sec
pub
Prior art date
Application number
ZA9606577A
Other languages
English (en)
Inventor
Mark William James Ferguson
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10778809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA966577(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of ZA966577B publication Critical patent/ZA966577B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Prostheses (AREA)
  • Peptides Or Proteins (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
ZA9606577A 1995-08-04 1996-08-02 Pharmaceutical composition. ZA966577B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516073A GB2304045A (en) 1995-08-04 1995-08-04 Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Publications (1)

Publication Number Publication Date
ZA966577B true ZA966577B (en) 1998-02-02

Family

ID=10778809

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606577A ZA966577B (en) 1995-08-04 1996-08-02 Pharmaceutical composition.

Country Status (13)

Country Link
US (1) US6060460A (fr)
EP (1) EP0841937B2 (fr)
JP (1) JP4189030B2 (fr)
AT (1) ATE275964T1 (fr)
AU (1) AU717204B2 (fr)
CA (1) CA2228650A1 (fr)
DE (1) DE69633392T3 (fr)
DK (1) DK0841937T4 (fr)
ES (1) ES2227601T5 (fr)
GB (1) GB2304045A (fr)
PT (1) PT841937E (fr)
WO (1) WO1997005892A1 (fr)
ZA (1) ZA966577B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
AU777166B2 (en) * 1999-12-15 2004-10-07 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
WO2002030432A1 (fr) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent pour reduire la formation de cicatrices par alcalinisation de plaies
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
WO2019236837A1 (fr) * 2018-06-06 2019-12-12 Emory University Compositions de récepteur du facteur de croissance transformant bêta-3, et utilisations pour l'ossification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004748A1 (fr) † 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITION DE FACTEUR β DE CROISSANCE A TRANSFORMATION AFIN D'EMPECHER L'ACCUMULATION DE MATRICE EXTRACELLULAIRE
WO1991010727A1 (fr) † 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibiteurs de facteurs regulateurs cellulaires
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JP4124815B2 (ja) † 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
ES2188585T3 (es) † 1991-11-14 2003-07-01 Jolla Cancer Res Found Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices.
AU3178893A (en) * 1991-11-15 1993-06-15 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
CA2146973C (fr) * 1992-10-29 2008-09-02 Patricia R. Segarini Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
AU8016894A (en) * 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity

Also Published As

Publication number Publication date
ES2227601T5 (es) 2009-06-08
DE69633392T3 (de) 2009-08-13
ATE275964T1 (de) 2004-10-15
DE69633392T2 (de) 2005-09-22
DK0841937T3 (da) 2004-10-18
DK0841937T4 (da) 2009-05-11
US6060460A (en) 2000-05-09
GB2304045A (en) 1997-03-12
JP2000500162A (ja) 2000-01-11
CA2228650A1 (fr) 1997-02-20
PT841937E (pt) 2004-11-30
WO1997005892A1 (fr) 1997-02-20
ES2227601T3 (es) 2005-04-01
JP4189030B2 (ja) 2008-12-03
AU6624996A (en) 1997-03-05
AU717204B2 (en) 2000-03-23
EP0841937B2 (fr) 2009-01-14
EP0841937B1 (fr) 2004-09-15
EP0841937A1 (fr) 1998-05-20
DE69633392D1 (de) 2004-10-21
GB9516073D0 (en) 1995-10-04

Similar Documents

Publication Publication Date Title
AU678795B2 (en) Application of riluzole in the treatment of neurological lesions related to traumatic injuries
AU6666096A (en) Pharmaceutical composition containing il-10
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
BG102726A (en) Combined therapy for osteoporosis
AU6357596A (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
AU7313896A (en) Pharmaceutical composition containing an activin or inhibin stimulator
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
AU6624896A (en) Pharmaceutical composition
GB9516073D0 (en) Pharmaceutical composition
AU3166295A (en) Imidazopyridine-azolidinones
AU4178497A (en) HTm4, methods of treatment and assays, agonists and antagonists
AU5760596A (en) Component b as cicatrizant
AU3267097A (en) Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use